Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on May 9, 2019. The report announces financial results for the quarter ended March 31, 2019. The company is an emerging growth company with common stock (Symbol: ARPO) traded on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. It serves solely as a notification that the quarterly results have been announced and the press release is available.
Guidance, Outlook, and Risks
The text does not include management commentary, guidance, outlook, or specific risk factors. It explicitly states that the information in this report and the attached press release is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the press release (Exhibit 99.1) referenced in this filing.
- Confirm the company name is Aerpio Pharmaceuticals, Inc., as the input metadata incorrectly listed Whitehawk Therapeutics, Inc.
- Review the full press release for any updates on clinical trial progress or pipeline developments not detailed in this summary.
- Check the Nasdaq Capital Market for the current trading status of the ARPO ticker.